Whalesbook
Mediation ki koshish shuru, ab kya hoga?
Dekho, IHH Healthcare ne ab ek smart move kiya hai. Woh apne sabse bade shareholder, Mitsui & Co. se request kar rahe hain ki woh Japanese drugmaker Daiichi Sankyo ke saath deal karwane mein help karein. Ye move tab aaya hai jab India aur Japan mein kaafi legal battles chal rahi hain. IHH ki subsidiary NTK, 200 billion JPY (lagbhag ₹11,800 Crore) ka damages claim kar rahi hai. Ye poora chakkar IHH ke 2018 mein Fortis Healthcare ko kharidne ki deal mein gadbad hone ki wajah se shuru hua tha. Reports ke mutabik, Daiichi Sankyo ne IHH ki open offer rokne mein interfere kiya tha, jiski wajah se ye sab shuru hua.
Mitsui hi kyun ban rahe hain middle-man?
Ab sawal ye hai ki Mitsui & Co. hi bicholiya kyun ban rahe hain? Toh bhai, woh Daiichi Sankyo ke saath already business mein hain, isliye IHH ko lagta hai ki woh aasani se baat kar payenge. Ye poora dispute ek bade legal saga ka hissa hai, jisme Daiichi Sankyo aur Singh brothers ke beech Ranbaxy ki 2008 ki sale ko lekar dispute tha, jiski wajah se arbitration awards aur Fortis trademark ki auction jaisi cheezein hui hain.
Market kya kehta hai?
IHH Healthcare ki market value around MYR 77.58 billion hai, aur iska P/E ratio 36.8x se 42.45x ke beech chal raha hai. Ye dikhata hai ki investors ko iski growth par bharosa hai, khas kar India jaise markets mein. India ka healthcare sector IHH ke liye ek bada growth area hai, jo 2023 mein $178 billion ka tha aur 2026 tak $610 billion se upar jaane ka estimate hai. Dusri taraf, Daiichi Sankyo ki market cap lagbhag ¥5 trillion hai, aur iska P/E ratio 15.44x se 18.69x ke beech hai. Analysts IHH ko 'Buy' rating de rahe hain aur price targets mein upside dikha rahe hain.
Risk factor aur Valuation
Ye case ₹11,800 Crore tak ja sakta hai, jo IHH ke liye ek bada financial risk hai. Daiichi Sankyo Singh brothers se arbitration awards vasool karne mein kaafi serious hai, jisme Fortis trademark ki auction bhi shamil hai. Ye sab purane business deals se juda hai aur is mediation ka result kya hoga, ye dekhna padega.
Bhale hi IHH keh raha hai ki woh apne kaam par focus kar rahe hain aur unka koi distraction nahi hai, lekin legal costs badh sakte hain. Daiichi Sankyo ke bhi apne financial risks hain, jaise ki ek development-stage product ke liye ¥12.7 billion ka provision. IHH ka higher P/E ratio dikhata hai ki woh growth par zyada depend karte hain, isliye lambi legal ladai unke valuation ke liye khatarnak ho sakti hai. IHH ka Mitsui par nirbhar rehna ye bhi batata hai ki direct baat karne mein mushkil ho rahi hai. IHH ki Fortis Mandatory Tender Offer ko poora karna bhi is legal chakkar par depend karta hai.
Aage kya? Growth vs Risk
Ab IHH Healthcare ko ek balance banana padega: ek taraf apni growth plans chalana, aur doosri taraf Daiichi Sankyo se deal ka risk manage karna. Mitsui ki involvement se mediation kitni successful hoti hai, ye important hoga. Analysts filhaal IHH ke liye positive hain. Daiichi Sankyo ka future unke drug pipeline par depend karta hai. Is dispute ka resolution dono companies ke future ke liye bohot impact karega.